1-20 of 93
David Siegel
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Ex Vivo Enriched Tumor Antigen-Specific T Cells Are Optimal Effectors of T Cell Engagers and Tumor-Specific T Cell Receptor/T Cell Engager Combination Provides Synergistic Efficacy Against Hematologic Malignancies

Manpreet Bariana, Mark Batistick, Mathias Oelke, Sojung Kim, Elena Cassella, Sidharth Anand, Shaina Anuncio, Ashley Varkey, Ruipeng Wang, Jack Ragheb, David Siegel, Johannes Zakrzewski
Journal: Blood
Blood (2023) 142 (Supplement 1): 2056.
https://doi.org/10.1182/blood-2023-179342
Published: 2023
Journal Articles

Outcomes of Patients with Heavily Pretreated Relapsed/Refractory Multiple Myeloma Receiving Salvage Cytotoxic Therapy with Supportive Stem Cell Boost

Ayrton Bangolo, Samir Oza, Ronit Slotky, Aimee Chappell, David Siegel, Harsh Parmar, Noa Biran, David H. Vesole, Pooja Phull
Journal: Blood
Blood (2022) 140 (Supplement 1): 10041–10042.
https://doi.org/10.1182/blood-2022-171012
Published: 2022
Journal Articles

Gut Microbiome Composition Is Associated with Engraftment Syndrome in Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation

Rena Feinman, Ariel A. Aptekmann, Iriana Colorado, Samuel Roy, Joshua Zenreich, Sophia H. Dar, Adolfo Aleman, Rashmi Unawane, Margaret Zhuang, Megan Korkoleo, Mariefel Vendivil, Andrea Ricourt, Andrew McConnell, Phyllis McKiernan, Anqi Dai, Andrew L. Pecora, Noa Biran, David Siegel, Jonathan U. Peled, Michele L. Donato
Journal: Blood
Blood (2022) 140 (Supplement 1): 4843–4844.
https://doi.org/10.1182/blood-2022-168934
Published: 2022
Journal Articles

Effect of Daratumumab on Stem Cell Mobilization and Engraftment Kinetics Post Autologous Stem Cell Transplantation in Patients with Newly Diagnosed Multiple Myeloma

Samir Oza, Ronit Slotky, Pranay Vissa, Pooja Phull, Sukhdeep Kaur, Hyung C. Suh, Michele L. Donato, Scott D. Rowley, Noa Biran, David H. Vesole, David Siegel, Harsh Parmar
Journal: Blood
Blood (2022) 140 (Supplement 1): 10441–10442.
https://doi.org/10.1182/blood-2022-171098
Published: 2022
Journal Articles

KarMMa-2 Cohort 2c: Efficacy and Safety of Idecabtagene Vicleucel in Patients with Clinical High-Risk Multiple Myeloma Due to Inadequate Response to Frontline Autologous Stem Cell Transplantation

Madhav Dhodapkar, Melissa Alsina, Jesus Berdeja, Krina Patel, Ravi Vij, Xavier Leleu, Anna Truppel-Hartmann, Debashree Basudhar, Ethan Thompson, Xirong Zheng, Revathi Ananthakrishnan, Linda Favre-Kontula, Chiara Greggio, Lars Sternas, David Siegel
Journal: Blood
Blood (2022) 140 (Supplement 1): 7441–7443.
https://doi.org/10.1182/blood-2022-162615
Published: 2022
Journal Articles

Cost-Effectiveness Analysis of Motixafortide Versus Plerixafor in Stem Cell Mobilization for Autologous Transplantation in Patients with Multiple Myeloma

Mark Lamotte, John F. DiPersio, David Siegel, Haddas Meron, Laetitia Gerlier
Journal: Blood
Blood (2022) 140 (Supplement 1): 10794–10795.
https://doi.org/10.1182/blood-2022-166865
Published: 2022
Journal Articles

The Clinical Characteristics and Epidemiology of Extramedullary Multiple Myeloma over the Past Two Decades

Ayrton Bangolo, Pierre Fwelo, Chinmay Trivedi, Jennifer Hashem, Parul Jandir, Katamon Klaichart, Rua Abdelrahim, Ayodya R Perera, Manbir Singh, Rohini B Gurumoorthy, Apurva Tiwari, Sudha S Konakanchi, Nagihan Orhun, Adithya Polavarapu, Ritika Sharma, Ankit Sarkar, Anupama Gupta, Bob-Hallen E. Treisma, Thin Thiri Soe, Ashwin Penchala, Sheetal Penmetsa, Srikar Bathi, Padmavathi Muppalla, David Siegel, Noa Biran, Harsh Parmar, David H. Vesole, Simcha Weissman, Pooja Phull
Journal: Blood
Blood (2022) 140 (Supplement 1): 12521–12522.
https://doi.org/10.1182/blood-2022-170783
Published: 2022
Journal Articles

Targeted Nanotherapy of Hematologic Malignancies Using Gold Nanoframework-Based Delivery of a Novel NF-Kb Inhibitor

Manpreet Bariana, Beilu Zhang, Jingyu Sun, Elena Cassella, Janice Rateshwar, Ming Tony Tan, Weiwei Wang, Jinping Wang, Rena Feinman, David Siegel, Hsiou-Chi Liou, Samedy Ouk, Patrizia Mondello, Hongjun Wang, Johannes Zakrzewski
Journal: Blood
Blood (2022) 140 (Supplement 1): 6018–6019.
https://doi.org/10.1182/blood-2022-160324
Published: 2022
Journal Articles

Carfilzomib vs bortezomib in patients with multiple myeloma and renal failure: a subgroup analysis of ENDEAVOR

Clinical Trials & Observations
Meletios Dimopoulos, David Siegel, Darrell J. White, Ralph Boccia, Karim S. Iskander, Zhao Yang, Amy S. Kimball, Khalid Mezzi, Heinz Ludwig, Ruben Niesvizky
Journal: Blood
Blood (2019) 133 (2): 147–155.
https://doi.org/10.1182/blood-2018-06-860015
Published: 2019
Includes: Supplemental data
Journal Articles

Safety and efficacy of selinexor in relapsed or refractory multiple myeloma and Waldenstrom macroglobulinemia

Clinical Trials & Observations
Christine Chen, David Siegel, Martin Gutierrez, Meagan Jacoby, Craig C. Hofmeister, Nashat Gabrail, Rachid Baz, Morten Mau-Sorensen, Jesus G. Berdeja, Michael Savona, Lynn Savoie, Suzanne Trudel, Nuchanan Areethamsirikul, T. J. Unger, Tami Rashal, Tim Hanke, Michael Kauffman, Sharon Shacham, Donna Reece
Journal: Blood
Blood (2018) 131 (8): 855–863.
https://doi.org/10.1182/blood-2017-08-797886
Published: 2018
Includes: Supplemental data
Journal Articles

Incidence and Survival Impact of Self-Reported Symptom and Psychological Distress Among Patients with Multiple Myeloma

Joshua R Richter, MD, Noa Biran, MD, Dhakshila Paramanathan, Srikesh Arunajadai, PhD, Victoria DeVincenzo, Ruth Pe Benito, Brooke Gruman, Sukhi Kaur, John Hervey, Eric Schultz, Scott Paddock, Andrew L. Pecora, MD, David H. Vesole, MD, David Siegel, MD PhD, Stuart L. Goldberg, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 679.
https://doi.org/10.1182/blood.V130.Suppl_1.679.679
Published: 2017
Journal Articles

Durable Clinical Responses in Heavily Pretreated Patients with Relapsed/Refractory Multiple Myeloma: Updated Results from a Multicenter Study of bb2121 Anti-Bcma CAR T Cell Therapy

Jesus G. Berdeja, MD, Yi Lin, MD PhD, Noopur Raje, MD, Nikhil Munshi, MD, David Siegel, MD PhD, Michaela Liedtke, MD, Sundar Jagannath, MD, Marcela V. Maus, MD PhD, Ashley Turka, Lyh Ping Lam, PharmD, RPh, Kristen Hege, MD, Richard A. Morgan, PhD, Michael Travis Quigley, James N. Kochenderfer, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 740.
https://doi.org/10.1182/blood.V130.Suppl_1.740.740
Published: 2017
Journal Articles

Overall Survival (OS) of Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Treated with Carfilzomib, Lenalidomide, and Dexamethasone (KRd) Versus Lenalidomide and Dexamethasone (Rd): Final Analysis from the Randomized Phase 3 Aspire Trial

A. Keith Stewart, MBChB, MBA, David Siegel, MD PhD, Heinz Ludwig, MD, Thierry Facon, MD, Hartmut Goldschmidt, MD, Andrzej J. Jakubowiak, MD, Jesus F. San Miguel, MD, Mihaela Obreja, Julie Blaedel, Meletios A. Dimopoulos
Journal: Blood
Blood (2017) 130 (Supplement 1): 743.
https://doi.org/10.1182/blood.V130.Suppl_1.743.743
Published: 2017
Journal Articles

Gene Expression Profiling (GEP) As a Prognostic Indicator of Multiple Myeloma, Irrespective of Disease Stage, Prior Treatment and Prior Transplant - a Single Center Experience

Miguel Gonzalez Velez, MD, Tracy Andrews, PhD, Narjust Duma, MD, Ning Dong, MD, Badal Thakkar, MD MPH, Giselle Suero, MD PhD, Joshua R Richter, MD, David H. Vesole, MD PhD, David Siegel, MD PhD, Noa Biran, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 3062.
https://doi.org/10.1182/blood.V130.Suppl_1.3062.3062
Published: 2017
Journal Articles

Safety and Efficacy of Pomalidomide (POM) + Low-Dose Dexamethasone (LoDEX) + Daratumumab (DARA) As Second- or Third-Line Therapy in Patients with Relapsed and/or Refractory Multiple Myeloma (RRMM) after Lenalidomide (LEN)-Based Treatment (Tx) Failure

David Siegel, MD PhD, Gary J. Schiller, MD, Christy Samaras, Michael Sebag, MD PhD, Jesus G. Berdeja, MD, Siddhartha Ganguly, MD, Jeffrey V. Matous, MD, Kevin W Song, MD, Christopher S. Seet, Giampaolo Talamo, Shanthi Srinivas, Mirelis Acosta-Rivera, Michael Bar, Donald Quick, Bertrand Anz, Gustavo Fonseca, Donna Reece, MD FRCP(C), Jorge Mouro, MS, Amit Agarwal, MD PhD, Faiza Zafar, MPAS, Max Qian, Anjan Thakurta, PhD, Nizar J. Bahlis, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 1811.
https://doi.org/10.1182/blood.V130.Suppl_1.1811.1811
Published: 2017
Journal Articles

Pomalidomide (POM) + Low-Dose Dexamethasone (LoDEX) Safety and Efficacy in Patients (pts) with Relapsed and/or Refractory Multiple Myeloma (RRMM) Previously Treated with a Proteasome Inhibitor (PI) and in Whom Last Prior Therapy with Lenalidomide (LEN) Failed

David Siegel, MD PhD, Gary J. Schiller, MD, Kevin W Song, MD, Richy Agajanian, Ketih Stockerl-Goldstein, Hakan Kaya, Michael Sebag, MD PhD, Christy Samaras, Ehsan Malek, MD, Giampaolo Talamo, Christopher S. Seet, Jorge Mouro, MS, Faiza Zafar, MPAS, Weiyuan Chung, Shankar Srinivasan, PhD, Max Qian, Amit Agarwal, MD PhD, Anjan Thakurta, PhD, Nizar J. Bahlis, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 1812.
https://doi.org/10.1182/blood.V130.Suppl_1.1812.1812
Published: 2017
Journal Articles

Outcomes of Autologous Stem Cell Transplantation in Very Elderly Patients with Multiple Myeloma

Phyllis McKiernan, APN, MSN, David Siegel, MD PhD, David H. Vesole, MD PhD, Scott D. Rowley, MD, Tracy Andrews, PhD, Andrea Ortega, RN, Alan P Skarbnik, MD, Noa Biran, MD, Joshua R Richter, MD, Andrew L. Pecora, MD, Andre Goy, MD, Rima M Panchal, MD, Nino Aleksidze, MD, Michele L. Donato, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 2013.
https://doi.org/10.1182/blood.V130.Suppl_1.2013.2013
Published: 2017
Journal Articles

Immune Profile of Patients (pts) with Relapsed and/or Refractory Multiple Myeloma (RRMM) Treated with Pomalidomide (POM) + Low-Dose Dexamethasone (LoDEX) + Daratumumab (DARA) in the Second Line Immediately after Lenalidomide (LEN)

Xiaozhong Qian, Kathryn Newhall, PhD, Mark Tometsko, Chad Bjorklund, Jianglin Ma, Nizar J. Bahlis, MD, David Siegel, MD PhD, Gary J. Schiller, MD, Christy Samaras, Michael Sebag, MD PhD, Jesus G. Berdeja, MD, Siddhartha Ganguly, MD, Jeffrey V. Matous, MD, Kevin W Song, MD, Christopher S. Seet, Giampaolo Talamo, Shanthi Srinivas, Mirelis Acosta-Rivera, Michael Bar, Donald Quick, Bertrand Anz, Gustavo Fonseca, Donna Reece, MD FRCP(C), Jorge Mouro, MS, Amit Agarwal, MD PhD, Faiza Zafar, MPAS, Anjan Thakurta, PhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 1888.
https://doi.org/10.1182/blood.V130.Suppl_1.1888.1888
Published: 2017
Journal Articles

Utility of Clinical-Grade Sequencing of Relapsed Multiple Myeloma Patients; Interim Analysis of the Multiple Myeloma Research Foundation (MMRF) Molecular Profiling Protocol

Daniel Auclair, PhD, Sikander Ailawadhi, Jesus G. Berdeja, MD, Xuhong Cao, Craig E. Cole, MD, Craig C Hofmeister, MDMPH, Sundar Jagannath, MD, Andrzej J. Jakubowiak, MD, Amrita Krishnan, MD, Shaji K Kumar, MD, Moshe Levy, MD, Sagar Lonial, MD, Gregory Orloff, MD, Dan Robinson, PhD, David Siegel, MD PhD, Suzanne Trudel, MD FRCP(C), Saad Z Usmani, MD, Ravi Vij, MDMBA, Jeffrey Lee Wolf, MD, Jennifer Yesil, MS, Jeffrey A Zonder, MD, Arul Chinnaiyan, MD, P. Leif Bergsagel, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 395.
https://doi.org/10.1182/blood.V130.Suppl_1.395.395
Published: 2017
Journal Articles

Patients Responding to Any First Line Therapy for Multiple Myeloma Should Proceed to Autologous Stem Cell Transplantation Instead of Receiving Second Line Therapy to Deepen Response

Nino Aleksidze, MD, Phyllis McKiernan, APN, MSN, David Siegel, MD PhD, Scott D. Rowley, MD, David H. Vesole, MD PhD, Tracy Andrews, PhD, Andrea Ortega, RN, Alan P Skarbnik, MD, Noa Biran, MD, Joshua R Richter, MD, Andrew L. Pecora, MD, Andre Goy, MD, Rima M Panchal, MD, Michele L. Donato, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 4538.
https://doi.org/10.1182/blood.V130.Suppl_1.4538.4538
Published: 2017